Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 7 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 11919868

    Heterocyclic compounds and related methods

    Recursion Pharmaceuticals, Inc. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  2. US 11919927

    Prefusion-stabilized hMPV F proteins

    The Board of Regents of the University of Texas System · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  3. US 11918571

    Compounds and their methods of use

    PRAXIS PRECISION MEDICINES, INC. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  4. US 11920139

    Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  5. US 11920134

    Compositions and methods for inhibiting expression of RRM2 genes

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 5, 2024 · Expires Feb 29, 2044

    granted
  6. US 11911403

    Antisense-induced exon exclusion in type VII collagen

    Sarepta Therapeutics, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  7. US 11912997

    RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  8. US 11912750

    GDNF fusion polypeptides and methods of use thereof

    Keros Therapeutics, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  9. US 11904052

    Methods for ameliorating infusion reactions

    ARBUTUS BIOPHARMA CORPORATION · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  10. US 11897969

    Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury

    The Regents of the University of California · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  11. US 11897875

    Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  12. US 11891399

    Inhibitors of cancer invasion, attachment, and/or metastasis

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  13. US 11885861

    3-dimensional representations of post-contrast enhanced brain lesions

    The Board of Regents of the University of Texas System · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  14. US 11884919

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  15. US 11884944

    Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof

    DENALI THERAPEUTICS INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  16. US 11878998

    Prefusion RSV F proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted
  17. US 11878074

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Jan 23, 2024 · Expires Jan 18, 2044

    granted
  18. US 11873495

    Compounds and methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 16, 2024 · Expires Jan 11, 2044

    granted
  19. US 11866688

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  20. US 11866439

    Ion channel modulators

    PRAXIS PRECISION MEDICINES, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  21. US 11866476

    Masked IL-2-Fc fusion polypeptides

    Xilio Development, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  22. US 11866747

    Engineered meganucleases that target human mitochondrial genomes

    Precision BioSciences, Inc. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  23. US 11866742

    Fusion proteins comprising enzyme replacement therapy enzymes

    DENALI THERAPEUTICS INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  24. US 11857697

    Compositions and methods for obtaining 3-dimensional lung-like epithelium and related uses thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted